X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ALEMBIC PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ALEMBIC PHARMA AJANTA PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 19.8 23.1 85.5% View Chart
P/BV x 4.5 6.1 74.7% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 AJANTA PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
ALEMBIC PHARMA
Mar-16
AJANTA PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,818792 229.6%   
Low Rs1,106443 249.7%   
Sales per share (Unadj.) Rs239.5167.0 143.4%  
Earnings per share (Unadj.) Rs52.838.2 138.3%  
Cash flow per share (Unadj.) Rs59.542.0 141.7%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs230.084.9 270.9%  
Shares outstanding (eoy) m88.77188.52 47.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.13.7 165.2%   
Avg P/E ratio x27.716.2 171.2%  
P/CF ratio (eoy) x24.614.7 167.1%  
Price / Book Value ratio x6.47.3 87.4%  
Dividend payout %010.5 0.0%   
Avg Mkt Cap Rs m129,782116,383 111.5%   
No. of employees `0006.8NA-   
Total wages/salary Rs m3,7654,214 89.3%   
Avg. sales/employee Rs Th3,128.4NM-  
Avg. wages/employee Rs Th554.0NM-  
Avg. net profit/employee Rs Th689.7NM-  
INCOME DATA
Net Sales Rs m21,25831,487 67.5%  
Other income Rs m24255 438.5%   
Total revenues Rs m21,49931,542 68.2%   
Gross profit Rs m6,58410,060 65.4%  
Depreciation Rs m596722 82.5%   
Interest Rs m437 11.1%   
Profit before tax Rs m6,2269,356 66.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5392,160 71.2%   
Profit after tax Rs m4,6867,194 65.1%  
Gross profit margin %31.031.9 96.9%  
Effective tax rate %24.723.1 107.1%   
Net profit margin %22.022.8 96.5%  
BALANCE SHEET DATA
Current assets Rs m12,23615,066 81.2%   
Current liabilities Rs m3,4617,674 45.1%   
Net working cap to sales %41.323.5 175.9%  
Current ratio x3.52.0 180.1%  
Inventory Days Days6067 89.9%  
Debtors Days Days8441 207.9%  
Net fixed assets Rs m11,1408,237 135.2%   
Share capital Rs m177377 46.9%   
"Free" reserves Rs m20,23715,416 131.3%   
Net worth Rs m20,41416,005 127.5%   
Long term debt Rs m100-   
Total assets Rs m24,48624,594 99.6%  
Interest coverage x1,519.4255.2 595.3%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 67.8%   
Return on assets %19.229.4 65.2%  
Return on equity %23.044.9 51.1%  
Return on capital %30.558.7 52.0%  
Exports to sales %055.7 0.0%   
Imports to sales %010.4 0.0%   
Exports (fob) Rs mNA17,551 0.0%   
Imports (cif) Rs mNA3,283 0.0%   
Fx inflow Rs m11,66717,811 65.5%   
Fx outflow Rs m1,6165,318 30.4%   
Net fx Rs m10,05212,493 80.5%   
CASH FLOW
From Operations Rs m2,8549,304 30.7%  
From Investments Rs m-2,604-3,105 83.9%  
From Financial Activity Rs m-2-1,959 0.1%  
Net Cashflow Rs m2484,240 5.9%  

Share Holding

Indian Promoters % 73.8 74.1 99.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 2.9 53.4%  
FIIs % 7.6 9.1 83.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 13.9 122.3%  
Shareholders   20,968 49,328 42.5%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   BIOCON LTD  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 20, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS